INNOVIVA, INC. Disposal Group, Including Discontinued Operation, Revenue
INNOVIVA, INC. (INVA) reported Disposal Group, Including Discontinued Operation, Revenue of $0 for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-24.
Discontinued › Income Statement › Other Income
us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue · last filed 2016-02-24
- INNOVIVA, INC. disposal group, including discontinued operation, revenue for the quarter ending 2015-12-31 was $0.00.
- INNOVIVA, INC. disposal group, including discontinued operation, revenue for the quarter ending 2015-09-30 was $0.00.
- INNOVIVA, INC. disposal group, including discontinued operation, revenue for the quarter ending 2015-06-30 was $0.00, a 100.00% decline year-over-year.
- INNOVIVA, INC. disposal group, including discontinued operation, revenue for the quarter ending 2015-03-31 was $0.00, a 100.00% decline year-over-year.
- INNOVIVA, INC. disposal group, including discontinued operation, revenue for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- INNOVIVA, INC. disposal group, including discontinued operation, revenue for fiscal 2014 was $3.13M, a 1284.51% increase from fiscal 2013.
- INNOVIVA, INC. disposal group, including discontinued operation, revenue for fiscal 2013 was $226.00K, a 99.83% decline from fiscal 2012.
- INNOVIVA, INC. disposal group, including discontinued operation, revenue for fiscal 2012 was $130.15M.
| Period end | Disposal Group, Including Discontinued Operation, Revenue 3 month | Disposal Group, Including Discontinued Operation, Revenue 6 month | Disposal Group, Including Discontinued Operation, Revenue 9 month | Disposal Group, Including Discontinued Operation, Revenue 12 month |
|---|---|---|---|---|
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $0.00 derived: sum of 2 quarters · filed 2016-02-24 | $0.00 derived: sum of 3 quarters · filed 2016-02-24 | $0.00 10-K · filed 2016-02-24 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $0.00 derived: sum of 2 quarters · filed 2015-11-05 | $0.00 10-Q · filed 2015-11-05 | $0.00 derived: sum of 4 quarters · filed 2016-02-24 |
| 2015-06-30 | $0.00 10-Q · filed 2015-08-06 | $0.00 10-Q · filed 2015-08-06 | $0.00 derived: sum of 3 quarters · filed 2016-02-24 | $0.00 derived: sum of 4 quarters · filed 2016-02-24 |
| 2015-03-31 | $0.00 10-Q · filed 2015-05-08 | $0.00 derived: sum of 2 quarters · filed 2016-02-24 | $0.00 derived: sum of 3 quarters · filed 2016-02-24 | $2.18M derived: sum of 4 quarters · filed 2016-02-24 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $0.00 derived: sum of 2 quarters · filed 2016-02-24 | $2.18M derived: sum of 3 quarters · filed 2016-02-24 | $3.13M 10-K · filed 2016-02-24 |
| 2014-09-30 | $0.00 10-Q · filed 2014-11-04 | $2.18M derived: sum of 2 quarters · filed 2015-08-06 | $3.13M 10-Q · filed 2015-11-05 | $3.30M derived: sum of 4 quarters · filed 2016-02-24 |
| 2014-06-30 | $2.18M 10-Q · filed 2015-08-06 | $3.13M 10-Q · filed 2015-08-06 | $3.30M derived: sum of 3 quarters · filed 2016-02-24 | $3.33M derived: sum of 4 quarters · filed 2016-02-24 |
| 2014-03-31 | $945.00K 10-Q · filed 2015-05-08 | $1.12M derived: sum of 2 quarters · filed 2016-02-24 | $1.14M derived: sum of 3 quarters · filed 2016-02-24 | $1.15M derived: sum of 4 quarters · filed 2016-02-24 |
| 2013-12-31 | $175.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $199.00K derived: sum of 2 quarters · filed 2016-02-24 | $204.00K derived: sum of 3 quarters · filed 2016-02-24 | $226.00K 10-K · filed 2016-02-24 |
| 2013-09-30 | $24.00K 10-Q · filed 2014-11-04 | $29.00K derived: sum of 2 quarters · filed 2014-11-04 | $51.00K 10-Q · filed 2014-11-04 | |
| 2013-06-30 | $5.00K 10-Q · filed 2014-08-07 | $27.00K 10-Q · filed 2014-08-07 | ||
| 2012-12-31 | $130.15M 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |